Want to see GB:FAB full AI Analyst Report?
FAB Stock Chart & Stats
11.25 p
0.65 p(6.05%)
At close: 4:00 PM EDT
11.25 p
0.65 p(6.05%)
Day’s Range― - ―
52-Week Range9.00 p - 20.00 p
Previous CloseN/A
Volume23.22K
Average Volume (3M)469.16K
Market Cap
£15.02M
Enterprise Value13.92 p
Total Cash (Recent Filing)£1.04M
Total Debt (Recent Filing)£331.00K
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Dec 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,156,876
10 Day Avg. Volume491,597
30 Day Avg. Volume469,162
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)8.89
Price to Sales (P/S)6.83
P/FCF Ratio-12.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.10M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross-margin ReboundThe sharp rebound in revenue and gross margin indicates improved recent demand and delivery economics across the company’s services. If retained, stronger gross profitability could provide a better base for funding research capacity and moving toward eventual operating leverage.
Contained LeverageRelatively modest leverage gives Fusion Antibodies more financial flexibility than a heavily debt-funded business. This can reduce pressure from financing obligations and preserve options to support operations or invest in its antibody discovery and development capabilities.
Broad Antibody Service OfferingA service range covering discovery through development support allows the company to address multiple stages of customers’ antibody programs. This breadth can deepen client relationships, create repeat project opportunities, and support relevance across therapeutic and diagnostic applications.
Bears Say
Severe Operating LossesVery negative operating and net margins show that the recent revenue recovery has not yet translated into sustainable profitability. Continued losses can consume equity, restrict internally funded investment, and leave results highly sensitive to further changes in project volume.
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business is not yet funding itself through customer activity. Reliance on external funding may persist, potentially limiting strategic flexibility and increasing the importance of achieving better cash conversion.
Volatile Revenue And Limited ScaleThe multi-year revenue pattern indicates that growth has not yet become consistent or sufficient to establish sustainable scale. Volatility makes capacity planning and earnings visibility more difficult, while persistent losses suggest the current business base remains economically fragile.
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 9.00 p and its highest was 20.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £15.02M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Dec 07, 2026 which is in 67 days.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Sep 14, 2026. The company reported -0.005 p earnings per share for the quarter.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,156,876 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report. Following the earnings report the stock price went down -21.277%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Scancell Holdings
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―